Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV)

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 7, 2010, Pages e268-e271

  Choi, Mi Rim ^a   Jiles, Cynthia ^a   Seibel, Nita L ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Antiemetics; Aprepitant; Chemotherapy induced nausea and vomiting; Pediatric

Indexed keywords

APREPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; IFOSFAMIDE; ONDANSETRON; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE 21-PHOSPHATE; DEXAMETHASONE SODIUM PHOSPHATE; DRUG DERIVATIVE; GLUCOCORTICOID; MORPHOLINE DERIVATIVE; SEROTONIN 3 RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; SCHOOL CHILD; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG COMBINATION; NAUSEA; NEOPLASM; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MORPHOLINES; NAUSEA; NEOPLASMS; RECEPTORS, SEROTONIN, 5-HT3; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VOMITING;

EID: 77958174965     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181e5e1af     Document Type: Article

References (22)

1. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999; 17: 2971-2994.
2. Hickok JT, Roscoe JA, Morrow GR, et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5- hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer. 2003; 97: 2880-2886.
3. de Wit R, Schmitz PI, Verweij J, et al. Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained. J Clin Oncol. 1996; 14: 644-651.
4. de Wit R, van den Berg H, Burghouts J, et al. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br J Cancer. 1998; 77: 1487-1491.
5. Massaro AM, Lenz KL. Aprepitant: a novel antiemetic for chemotherapy induced nausea and vomiting. Ann Pharmacother. 2005; 39: 77-85.
6. Hesketh PJ, Gralla RJ, Webb RT, et al. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin induced emesis. J Clin Oncol. 1999; 17: 338-343.
7. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003; 97: 3090-3098.
8. Oechsle K, Muller MR, Hartmann JT, et al. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone. Onkologie 2006; 29: 557-561.
9. Smith AR, Repka TL, Weigel BJ. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr Blood Cancer 2005; 45: 857-860.
10. Gore L, Chawla S, Petrilli A, et al. Aprepitant in adolescent patients for prevention of chemotherapy -induced nausea and vomiting: a randomized, double-blinded, placebo controlled study of efficacy and tolerability. Pediatr Blood Cancer. 2009; 52: 242-247.
11. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006; 24: 2932-2947.
12. Ettinger DS, Bierman PJ, Bradbury B, et al. Antiemesis. J Natl Compr Canc Netw. 2007; 5: 12-33.
13. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008; 358: 2482-2494.
14. Navari RM. Pathogenesis-based treatment of Chemotherapy-Induced Nausea and Vomiting- Two New Agents. The J of Supp Oncol. 2003; 1: 89-103.
15. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003; 21: 4112-4119.
16. Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer. 2005; 41: 1278-1285.
17. Dupuis LL, Lingertat-Walsh K, Walker SE. Stability of an extemporaneous oral liquid aprepitant formulation. Support Care Cancer. 2009; 17: 701-706.
18. de Jonge ME, Huitema AD, Holtkamp MJ, et al. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol. 2005; 56: 370-378.
19. Loos WJ, de Wit R, Freedman SJ, et al. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol. 2007; 59: 407-412.
20. McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003; 74: 17-24.
21. Roila F, Feyer P, Maranzano E, et al. Antiemetics in children receiving chemotherapy. Support Care Cancer. 2005; 13: 129-131.
22. Small BE, Holdsworth MT, Raisch DW, et al. Survey ranking of emetogenic control of nausea and vomiting in children receiving combined cancer chemotherapy. J Pediatric Hematol Oncol. 2000; 22: 125-132.